← Back to Search

Proton Beam Therapy

Precision Radiotherapy for Non-Small Cell Lung Cancer (ASPIRE-ILD Trial)

N/A

Waitlist Available

Research Sponsored by Lawson Health Research Institute

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Eastern Cooperative Oncology Group (ECOG) performance status 0-3

Stage T1-2, N0, M0 (AJCC Staging, 8th Edition - i.e. tumor size ≤ 5 cm) prior to registration

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 8 years

Awards & highlights

ASPIRE-ILD Trial Summary

This trial will test a new cancer treatment in patients with Non-Small Cell Lung Cancer and Interstitial Lung Disease. Outcomes will be measured based on how well the treatment works and how safe it is.

Who is the study for?

This trial is for adults over 18 with early-stage Non-Small Cell Lung Cancer (NSCLC) and Interstitial Lung Disease (ILD). They should not be candidates for surgery, have a life expectancy of more than 6 months, and an ECOG performance status of 0-3. Excluded are those with other recent cancers, prior thoracic radiotherapy, or taking certain drugs that affect radiotherapy.Check my eligibility

What is being tested?

The study tests Stereotactic Ablative Radiotherapy (SABR) on NSCLC patients with ILD to see its effectiveness and safety. Participants are grouped based on their ILD-GAP index to assess outcomes specific to their condition's severity.See study design

What are the potential side effects?

Potential side effects include typical radiation-related issues such as skin irritation at the treatment site, fatigue, shortness of breath, chest pain, coughing up blood, and possible worsening of lung function due to pre-existing ILD.

ASPIRE-ILD Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I can care for myself but may not be able to do heavy physical work.

Select...

My cancer is early stage, with a tumor size of 5 cm or less and hasn't spread.

Select...

I am 18 years old or older.

Select...

I have been diagnosed with a type of lung scarring by a lung specialist.

ASPIRE-ILD Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 8 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~8 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and 8 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Overall Survival

Secondary outcome measures

Analysis of Outcomes for Patients Eligible for Study Who Decline Radiotherapy

Changes in ILD Severity measured by High Resolution Computed Tomography (HRCT)

Changes in Pulmonary Function Tests

+9 more

ASPIRE-ILD Trial Design

1Treatment groups

Experimental Treatment

Group I: Treatment Arm: Stereotactic Ablative RadiotherapyExperimental Treatment1 Intervention

Stereotactic ablative radiotherapy for early non-small cell lung cancer and interstitial lung disease

0 / 4Eligibility criteria met

Find a Location

Who is running the clinical trial?

Western University, CanadaOTHER

239 Previous Clinical Trials

57,444 Total Patients Enrolled

Lawson Health Research InstituteLead Sponsor

656 Previous Clinical Trials

413,389 Total Patients Enrolled

London Health Sciences CentreOTHER

142 Previous Clinical Trials

49,879 Total Patients Enrolled

Media Library

Stereotactic Ablative Radiotherapy (Proton Beam Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT03485378 — N/A

Interstitial Lung Disease Research Study Groups: Treatment Arm: Stereotactic Ablative Radiotherapy

Interstitial Lung Disease Clinical Trial 2023: Stereotactic Ablative Radiotherapy Highlights & Side Effects. Trial Name: NCT03485378 — N/A

Stereotactic Ablative Radiotherapy (Proton Beam Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03485378 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the total number of participants that have been recruited for this clinical research?

"This experimental protocol necessitates the participation of 39 qualified patients. These individuals may join this trial at UHN Princess Margaret Cancer Centre in Edmonton, Alberta or alternatively they can register with Alberta Health Services, Cross Cancer Institude in London, Quebec."

Answered by AI

Is there still room for enrolment in this clinical experiment?

"Affirmative. Clinicaltrials.gov illustrates that the study, which was initially advertised on September 20th 2018, is still seeking participants. At this moment in time, 39 patients need to be recruited from 5 distinct medical facilities."

Answered by AI

Are there any American institutions currently administering this research trial?

"Currently, 5 locations across Canada are recruiting patients for this medical trial. This includes the UHN Princess Margaret Cancer Centre in Edmonton and Alberta Health Services as well as Cross Cancer Institute in London and Lawson Health Research Institute's London Regional Cancer Program located in Montréal. Additionally, there are additional sites involved with this research endeavor."

Answered by AI

Recent research and studies

BMC CancerJournal

Assessment of Precision Irradiation in Early Non-small Cell Lung Cancer and Interstitial Lung Disease (ASPIRE-ILD): Study Protocol for a Phase II Trial

Palma, David A., Hanbo Chen, Houda Bahig, Stewart Gaede, Stephen Harrow, Joanna M. Laba, X. Melody Qu, et al.. 2019. “Assessment of Precision Irradiation in Early Non-small Cell Lung Cancer and Interstitial Lung Disease (ASPIRE-ILD): Study Protocol for a Phase II Trial”. BMC Cancer. Springer Science and Business Media LLC. doi:10.1186/s12885-019-6392-8.

clinicaltrials.govStudy

Assessment of Precision Irradiation in Early NSCLC and Interstitial Lung Disease

David Palma 2018. "Assessment of Precision Irradiation in Early NSCLC and Interstitial Lung Disease". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03485378.

All > Lung Disease